AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.009

-0.001-10.00%

Volume:414.93K

Turnover:4K

Market Cap:39.04M

PE:-0.47

High:0.010

Open:0.010

Low:0.009

Close:0.010

52wk High:0.040

52wk Low:0.009

Shares:4.34B

Float Shares:3.34B

Volume Ratio:0.10

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.019

EPS(LYR):-0.018

ROE:-174.71%

ROA:-49.84%

PB:1.58

PE(LYR):-0.49

Loading ...

Overview Company News Filings

Radiopharm Theranostics Prices Unregistered Warrants in Private Placement at Us$3.79 Per ADS

Radiopharm Theranostics Secures Nearly AU$13 Million Through Dual Institutional Capital Raise

MT Newswires Live

Radiopharm Theranostics Announces Concurrent Us$4.1 Million Registered Direct Offering and up to Additional A$12.7 (us$8.9) Million Australian Placement and Share Purchase Plan

THOMSON REUTERS

Radiopharm Theranostics Calls Extraordinary Shareholder Meeting

Radiopharm Theranostics - Receives Firm Commitments for A$12.5 Mln Capital Raising

THOMSON REUTERS

Radiopharm Theranostics - no Dose-limiting Toxicities Observed with Rad204 in Phase 1 Trial

THOMSON REUTERS

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of Rad204 in Patients with Advanced Solid Tumors Post-immunotherapy

THOMSON REUTERS

Radiopharm Theranostics Partners with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial

Radiopharm Theranostics Announces Positive Phase 2B Trial Results of Rad 101 for Diagnosis of Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics - Rad101 Shows Preliminary 86% Sensitivity in Six-month Follow-up; Specificity Data Expected Q4 2026

THOMSON REUTERS

Radiopharm Theranostics' Phase 2b Trial of Brain Metastases Diagnosis Agent Meets Primary Endpoint

MT Newswires Live

Radiopharm Theranostics - Requests Trading Halt Pending Announcement on Material Capital Raising

THOMSON REUTERS

Radiopharm Theranostics Receives AU$5.9 Million R&D Tax Refund for Fiscal Year 2025

MT Newswires Live

Starpharma Says Radiopharm Theranostics Collaboration Milestone Triggers AU$500,000 Option Fee

MT Newswires Live

Radiopharm Theranostics Ltd : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $16

THOMSON REUTERS

Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$29k

Simply Wall St.

Radiopharm Theranostics files Form 3 for Chief Medical Officer Dimitris Voliotis

Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement

Regis Healthcare to Benefit from Higher Govt Spending on Aged Care, Says Jefferies

MT Newswires Live

Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/RAD.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.009,"timestamp":1787897520000,"preClose":0.01,"halted":0,"volume":414931,"delay":0,"changeRate":-0.10000000000000009,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.019034,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"08-28 16:12:00 AEST","open":0.01,"high":0.01,"low":0.009,"amount":4018,"amplitude":0.1,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.019034,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1787875200000,1787896800000]],"volumeRatio":0.09938063354646137,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.01,"auctionPrice":0.01,"auctionVolume":90000,"auction":3,"marketStatus":"盘后竞价","timestamp":1787897387782}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-49.84%","roe":"-174.71%","lyrEps":-0.018424,"volumeRatio":0.09938063354646137,"shares":4337549000,"dividePrice":0,"high":0.01,"amplitude":0.1,"preClose":0.01,"low":0.009,"week52Low":0.009,"pbRate":"1.58","psRate":"3.09","week52High":0.04,"institutionHeld":0,"latestPrice":0.009,"eps":-0.019034,"divideRate":0,"volume":414931,"delay":0,"ttmEps":-0.019034,"open":0.01,"prevYearClose":0.025,"prevWeekClose":0.009,"prevMonthClose":0.014,"prevQuarterClose":0.019,"fiveDayClose":0.01,"twentyDayClose":0.014,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654301951","title":"Radiopharm Theranostics Prices Unregistered Warrants in Private Placement at Us$3.79 Per ADS","url":"https://stock-news.laohu8.com/highlight/detail?id=2654301951","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654301951?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:06","pubTimestamp":1785146819,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics prices unregistered warrants in private placement at US$3.79 per ADSRadiopharm Theranostics priced a concurrent private placement of unregistered warrants to buy 1,281,646 ADSs","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLvvvlB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654349067","title":"Radiopharm Theranostics Secures Nearly AU$13 Million Through Dual Institutional Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2654349067","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654349067?lang=en_us&edition=fundamental","pubTime":"2026-07-27 06:02","pubTimestamp":1785103327,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) secured firm commitments to raise around AU$12.5 million through a two-part institutional capital raising, comprising an Australian placement and a US direct register","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067","ADS.AU","BK7016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089441","title":"Radiopharm Theranostics Announces Concurrent Us$4.1 Million Registered Direct Offering and up to Additional A$12.7 (us$8.9) Million Australian Placement and Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653089441?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:15","pubTimestamp":1784891700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA2BTVJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089553","title":"Radiopharm Theranostics Calls Extraordinary Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089553","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653089553?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:01","pubTimestamp":1784890909,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics calls extraordinary shareholder meetingRadiopharm Theranostics will hold an extraordinary general meeting in Australia on Sept. 11, 2026.Shareholders will vote on approvals tie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL26pT5p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653704554","title":"Radiopharm Theranostics - Receives Firm Commitments for A$12.5 Mln Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704554?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:21","pubTimestamp":1784877673,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nFWN43P1FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754780","title":"Radiopharm Theranostics - no Dose-limiting Toxicities Observed with Rad204 in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754780?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA3MMWNN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754735","title":"Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of Rad204 in Patients with Advanced Solid Tumors Post-immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754735?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:05","pubTimestamp":1784718300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA3MMWNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754924","title":"Radiopharm Theranostics Partners with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754924","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754924?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718053,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialRadiopharm Theranostics partnered with Siemens Healthineers to manufacture and di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL3qgNlv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK7067","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","RAD.AU","LU2210150020.SGD","IE00BKPKM429.USD","BCDF","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754608","title":"Radiopharm Theranostics Announces Positive Phase 2B Trial Results of Rad 101 for Diagnosis of Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653754608?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA39F6Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653544827","title":"Radiopharm Theranostics - Rad101 Shows Preliminary 86% Sensitivity in Six-month Follow-up; Specificity Data Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653544827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653544827?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA39F6Y1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653364567","title":"Radiopharm Theranostics' Phase 2b Trial of Brain Metastases Diagnosis Agent Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2653364567","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653364567?lang=en_us&edition=fundamental","pubTime":"2026-07-22 13:09","pubTimestamp":1784696971,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said a phase 2b trial of RAD101 in participants with suspected recurrence of brain metastases after radiotherapy met its primary endpoint, according to a Wednesday filing with the Australian bourse.The analysis of the imaging data for all assessed lesions showed 93% concordance between magnetic resonance imaging and PET scans of brain metastases, per the filing.Meanwhile, 14 patients with evaluable six-month data showed preliminary sensitivity of 86%, a gauge of an imaging test's ability to correctly identify patients with disease.The results also showed \"substantial and selective tumor uptake of RAD101,\" supporting its progression into an intended registrational phase 3 program, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653789722","title":"Radiopharm Theranostics - Requests Trading Halt Pending Announcement on Material Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653789722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653789722?lang=en_us&edition=fundamental","pubTime":"2026-07-22 07:05","pubTimestamp":1784675104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nFWN43N173:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648601656","title":"Radiopharm Theranostics Receives AU$5.9 Million R&D Tax Refund for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2648601656","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648601656?lang=en_us&edition=fundamental","pubTime":"2026-07-03 14:39","pubTimestamp":1783060785,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) received its research and development (R&D) tax refund for the fiscal year 2025, totalling AU$5.9 million, including AU$104,475 in interest, according to a Friday Aus","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634744","title":"Starpharma Says Radiopharm Theranostics Collaboration Milestone Triggers AU$500,000 Option Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634744","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648634744?lang=en_us&edition=fundamental","pubTime":"2026-07-03 09:10","pubTimestamp":1783041039,"startTime":"0","endTime":"0","summary":"Starpharma Holdings (ASX:SPL) achieved a milestone under its collaboration with Radiopharm Theranostics (ASX:RAD), triggering an AU$500,000 option fee payable to Starpharma, according to a Friday fili","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPL.AU","BK7067","BK7501","RAD.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815964","title":"Radiopharm Theranostics Ltd : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640815964?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:11","pubTimestamp":1780567878,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7067","RADX","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636098872","title":"Despite Recent Gains, Radiopharm Theranostics Insiders Are Still Down AU$29k","url":"https://stock-news.laohu8.com/highlight/detail?id=2636098872","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636098872?lang=en_us&edition=fundamental","pubTime":"2026-05-17 08:24","pubTimestamp":1778977483,"startTime":"0","endTime":"0","summary":"Some of the losses seen by insiders who purchased AU$138.4k worth of Radiopharm Theranostics Limited ( ASX:RAD ) shares...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/despite-recent-gains-radiopharm-theranostics-insiders-are-st-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/despite-recent-gains-radiopharm-theranostics-insiders-are-st-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633641361","title":"Radiopharm Theranostics files Form 3 for Chief Medical Officer Dimitris Voliotis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633641361","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633641361?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:09","pubTimestamp":1778116170,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Form 3 showed Chief Medical Officer Dimitris Voliotis holding options to buy 22,972,000 ordinary shares at AUD 0.025, expiring July 1, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL65lPJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633674186","title":"Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633674186","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633674186?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:09","pubTimestamp":1778062182,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Paul Hopper reported 53.9 million ordinary shares held directly, with additional indirect holdings of 93.57 million shares via Kilinwata Investments Pty Ltd and 250,000 shares held by his spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL4NKFwh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633708962","title":"Regis Healthcare to Benefit from Higher Govt Spending on Aged Care, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2633708962","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633708962?lang=en_us&edition=fundamental","pubTime":"2026-05-05 07:14","pubTimestamp":1777936479,"startTime":"0","endTime":"0","summary":"Regis Healthcare  is expected to reap benefits from higher government funding into aged care sector, Jefferies said Monday in a note, adding that it is awaiting clarity from the upcoming federal budget announcement this month.The government has announced plans for a AU$3 billion investment in aged care, which includes an increased accommodation supplement.The investment firm assumes that if 40% of Regis' residents received a AU$15 higher daily accommodation supplement, the company could see around a 10% boost in EBITDA per place over 12 months. Regis expects fiscal 2026 underlying EBITDA of around AU$135 million.Jefferies is also confident in the company's fiscal 2027 outlook despite near-full occupancy as Regis continues to expand its portfolio and increase the proportion of residents paying Refundable Accommodation Deposit . The company reported average occupancy of 95.9% in mature homes in the third quarter.Jefferies maintained a buy rating and increased its price target by 35% to A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","XBI","LABU","LU0029874061.USD","BK4137","RAD.AU","HCSG","BK4581","LU0128526141.USD","RGS","BK4128","BK7113","RAD","BK7067","XLV","BK4192","REG.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632669690","title":"Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita","url":"https://stock-news.laohu8.com/highlight/detail?id=2632669690","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632669690?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:52","pubTimestamp":1777600337,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics CFO Aaron James Laurita reported 26,357 ordinary shares in an initial Form 3 filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLc8XzQv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}]}}